南征地那非治疗勃起功能障碍（ED）

阴蒂新上皮细胞（ED）冠心病更是举例来感叹常用Vardenafil（降服地那非）进行时用药对ED本品Sildenafil（西地那非）和Vardenafil（降服地那非）进行时举例来感叹比较科学学术研究，想要能够获取无性别歧视的结果。波士顿-2006年9翌年20日，学术研究结果公开发表在《官能华尔街日报》上，同时在埃及大马士革召开的官能医学国际协会第十一届大会上面世。这项学术研究非常独特，因为其图表来自一项关于PDE5（磷酸二脂酶5）消除本品的直接对比病因次测试，该次测试常用PDE5消除本品来用药ED冠心病。整个学术研究经过一个大使得针对每种本品的性别歧视超越这样一来。这是一项随机、双盲、交叉和直接对比的病因次测试，常用西地那非和降服地那非用药身患ED、冠心病、冠心病和/或高血脂的男官能冠心病，比较了二者的治果。结果表明在数个常用的有效官能指称标上降服地那非获取了统计学涵义上的优势，在治疗关注度和举例来感叹官能的多个评估测试之前，降服地那非的平庸并不比西地那非再加。总共1，057名男官能参与了这项学术研究，他们首先紧接著四个翌年份施打一种本品，然后是一个翌年份时间的缓冲期，接着再次紧接著四个翌年份施打另一种本品。治疗会被问道这样的缺陷：“总的来感叹，你更是喜欢常用那种本品？”此外还有其他11个有关ED用药的缺陷。利用预定常规进行时附加有效官能评估在数据分析之前也被常用。图表表明38.9%的治疗举例来感叹常用降服地那非，而34.5%的治疗希望常用西地那非（26.6%的治疗无举例来感叹官能）。在阴蒂新功能，关注度和上都关注度各个方面，降服地那非显著优于西地那非。在阴蒂时断开延展性，阴蒂可维持时间，全程可维持和阴蒂期望各个方面，降服地那非也有更是高比例的阳官能反应。这项学术研究的联合译者，官能华尔街日报的主编Irwin Goldstein 解释感叹：“该学术研究声称我们对PDE5消除本品病因区分的解读又前进了重要一步，称许了降服地那非用药ED的。”目前为止有三种PDE5消除本品可用于用药ED，它们分别是西地那非，他曾达那非和降服地那非。根据学术研究者的众感叹纷纭，所有这三种本品对一定范围内的人群都平庸出有效官能和耐受官能。来自直接对比的病因科学学术研究图表（如本项学术研究）非常稀少，然而这样的学术研究结果会为了让病因医生对西地那非、降服地那非和他曾达那非加以区分以选择最适合的本品供形态病冠心病常用。背景方法论：ED：阴蒂新上皮细胞 Erectile dysfunction, ED是指称停滞不能超越或者可维持阴蒂以满足。ED比过往用的"阳萎"（Impotence）一词更是确切，因为阳痿一词带有一定歧官能的字眼。ED可按其程度分为驭、之前、重三度，阳痿仅限于重度的ED。70年代后由于阴蒂认知和病因学术研究的十分困难，人们认清固然人际关系因素毕竟可以引致了ED，但对大多数男官能来感叹，ED与许多性疾病（冠心病，冠心病，心血管性疾病）、本品、部位及疗程等有关，因为阴蒂选择性是鼻腔消化道肿胀，食道扩大张，心悸减低和静脉回流受阻等完整血液物理现象每一次，在这一每一次之前，任何新上皮细胞的官能性疾病可以分为： 器质官能ED 血管官能因素：之外任何确实避免鼻腔食道心悸增大的性疾病，如：食道粥样硬化，食道重击，食道狭窄，食道并行及心新功能极度等，或内因静脉回流伸长选择性的白膜、贝壳窦内消化道增大所致的静脉溢。 神经官能因素：之前枢、上皮细胞病变疾病或重击皆可以避免阴蒂新上皮细胞。 疗程与部位：大血管疗程、癌根治术、腹阴茎癌根治术等疗程及骨盆脱臼、髋关节压缩官能脱臼或奔驰跨伤，可以引致了起有关的血管和神经重击，避免阴蒂新上皮细胞。 上皮细胞疾患、慢官能病和长期施打某些本品也可以引致了阴蒂新上皮细胞。 本身性疾病：如硬结症（Peyronie's disease）、侧向畸形、严重影响化脓和包皮饲养光。 人际关系官能ED 指称紧张、压力、抑郁、焦虑和夫妻感情不和等精神人际关系因素所引致的阴蒂新上皮细胞。 混合官能ED 指称精神人际关系因素和器质官能官能性疾病联合避免的阴蒂新上皮细胞。此外，由于器质官能ED未获取及时的用药糖尿治疗际关系压力过重，害怕收场，使ED用药更是加偏向复杂。国内举例来感叹628例ED冠心病官能性疾病分类的学术研究声称：人际关系官能分之二39%。器质官能为15.8%，混合官能分之二45.2%。PDE5消除剂PDE5是鼻腔之前消化道细胞内第二信使NO-cGMP的分解酶。PDE5消除剂能够减低cGMP的剂量，提升鼻腔消化道的舒张作用，并促进官能刺激诱发的阴蒂反应。PDE5消除剂类本品对ED用药很强最广泛的有效官能和耐受官能。因此，该类本品被当成口施打药本品的参考常规。目前为止，该类本品之外三种：西地那非、降服地那非和他曾达纳非。西地那非在1998年，降服地那非和他纳那非则是在2003年获取亚洲地区认证。在病因常用以及病因对照学术研究之前挖掘出，PDE5消除剂很强较再加的耐受官能和有效官能。在普通ED冠心病之前，病因学术研究充分证实上述三种本品的有效官能。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON -- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.主编：bluelove

主编： Zhu